Gender and Age Impacts on the Association Between Thyroid Function and Metabolic Syndrome in Chinese

Zhaowei Meng, MD, PhD, Ming Liu, MD, PhD, Qing Zhang, MD, Li Liu, MD, Kun Song, MD, Jian Tan, MD, Qiang Jia, MD, Guizhi Zhang, MD, Renfei Wang, MD, PhD, Yajing He, MD, Xiaojun Ren, MD, PhD, Mei Zhu, MD, PhD, Qing He, MD, PhD, Shen Wang, MD, Xue Li, MD, Tianpeng Hu, MD, Na Liu, MD, Arun Upadhyaya, MD, Pingping Zhou, MD, and Jianping Zhang, MD

Abstract: The relationship between thyroid dysfunction and metabolic syndrome (MS) is complex. We aimed to explore the impact of gender and age on their association in a large Chinese cohort.

This cross-sectional study enrolled 13,855 participants (8532 male, 5323 female), who self-reported as healthy without any known previous diseases. Clinical data including anthropometric measurements, thyroid function, and serum metabolic parameters were collected. The associations between thyroid function and MS of both genders were analyzed separately after dividing thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and age into subgroups. MS risks were calculated by binary logistic regression models.

Young males had significantly higher MS prevalence than females, yet after menopause, females had higher prevalence than males. Females had higher incidence of thyroid dysfunction than males. By using TSH quartiles as the categorical variables and the lowest quartile as reference, significantly increased MS risk was demonstrated in quartile 4 for males, yet quartiles 3 and 4 for females. By using FT3 quartiles as the categorical variables, significantly increased MS risk was demonstrated in quartile 2 to 4 for females only. By using age subgroups as the categorical variables, significantly increased MS risk was shown in both genders, with females (4.408–58.455) higher than males (2.588–4.943).

Gender and age had substantial influence on thyroid function and MS. Females with high TSH and high FT3 had higher MS risks than males. Aging was a risk for MS, especially for females. Urgent need is necessary to initiate interventional programs.

INTRODUCTION

The metabolic syndrome (MS) is a cluster of interrelated metabolic abnormalities, which is characterized by central obesity, hyperglycemia, hypertriglyceridemia, decreased high-density lipoprotein-cholesterol (HDL), and elevated blood pressure (BP). People with MS have an increased risk of cardiovascular disease, type 2 diabetes mellitus, and all-cause mortality. MS was first defined in 1998,1 which was then recognized by the American Heart Association and National Heart, Lung and Blood Institute in 2001.2 In 2005, MS definition was updated by American Diabetes Association to meet fasting glucose (FG) standard and to tailor waist circumference (WC) cut-points to specific ethnicity.3 And in 2009, a consensus criterion was reached by a joint statement from the above organizations,4 which was most commonly referred to nowadays. MS requires 3 of the following 5 factors to make a diagnosis: increased WC, elevated triglycerides (TG), reduced HDL, elevated BP, and elevated FG. Reports from China show that a large proportion of Chinese are suffering from MS, which has become an important health concern in China.5–8 Rapid economic development with accelerating changes in urbanization, nutrition, lifestyle, socio-economic status, and reduced physical activity must play crucial roles in the dramatic escalation of MS in China.6 Sex and age are also key factors in the development of MS. Sex difference in MS prevalence has been noticed, but some reports showed higher prevalence in men,7,8 while others showed higher prevalence in women.5,6 Besides, aging has been demonstrated with increasing MS prevalence.9,10 Therefore, we consider more investigation is needed to clarify the gender disparity, and confirm the role of aging.

There is a female preponderance in thyroid disorders, and its prevalence increases with age. Thyroid hormones have pleiotropic effects on lipid and glucose metabolism, blood pressure, and energy expenditure. Thyroid dysfunction is a risk
factor of cardiovascular disease. Recently, serum thyroid-stimulating hormone (TSH) is also found to be associated with adverse changes of lipid metabolism as well. The relationship between mild thyroid dysfunction and MS traits has become a hot topic of discussion recently, because both could increase morbidity and mortality. Patients with hypothyroidism and subclinical hypothyroidism were identified to have increased risks of MS. Even in euthyroid subjects, high normal TSH levels (>2.5 µIU/mL) were significantly associated with an increased prevalence of MS. Ruhla et al indicated that a TSH below 2.5 µIU/mL was associated with a favorable metabolic profile. Oh et al advocated that if healthy women had a TSH higher than 2.5 µIU/mL, assessment of MS should be done. However, there are reports with discordant results, which could not demonstrate such associations between TSH and MS. This inconsistency also warrants further analytical investigation on a bigger population.

The objective of our cross-sectional study was to investigate correlations between thyroid dysfunction and MS with emphasized focuses on differences generated from gender and age in a representative sample of Tianjin municipality population.

METHODS

Design
This cross-sectional, community-based health-check investigation was conducted in Tianjin Medical University General Hospital, under collaboration from the departments of Health Management, Endocrinology & Metabolism, and Nuclear Medicine, as reported before. All participants were required to complete a questionnaire and provide a blood sample. They were self-reported as healthy. In order to avoid the influence of confounding factors, the following criteria were used for exclusion: subjects with disease history of thyroid, liver, kidney, gastro-intestine, or oncology; subjects with any diseases or taking any medicine that might affect thyroid or metabolism (eg, antithyroid drugs, thyroid hormone, amiodarone, iodine, estrogen, androgen, statins, thyroid hormones, etc.); and pregnancy. During the period from September 2011 to March 2014, a total of 13,855 eligible subjects (8532 male, 5323 female) had adequate data for analysis. Written consents were obtained, and the institutional review board and ethic committee of Tianjin Medical University General Hospital approved this study.

Measurements
Anthropometric measurements and fasting blood tests of the participants were performed during their visits to our institution. Body height and body weight (BW) were measured in centimeters and kilograms. Body mass index (BMI) was calculated by dividing BW (kg) by the square of body height (m²). Fasting blood samples were obtained between 7 am and 10 am. TSH, free triiodothyronine (FT3), and free thyroxine (FT4) were determined by an auto-analyzer (Hitachi Model 7600 analyzer, Hitachi, Tokyo, Japan).

The laboratory reference ranges for parameters were as follows: TSH 0.3 to 5.0 µIU/mL; FT3 3.5 to 6.5 pmol/L; FT4 11.5 to 23.5 pmol/L; TC 3.59 to 5.18 mmol/L; TG 0.57 to 1.70 mmol/L; LDL 1.33 to 3.37 mmol/L; HDL 0.8 to 2.2 mmol/L; ALT 5 to 40 U/L; total bilirubin 3.4 to 20 µmol/L; BUN 1.7 to 8.3 mmol/L; UA 140 to 414 µmol/L; Cr 44 to 115 µmol/L; and FG 3.6 to 5.8 mmol/L.

DEFINITION
MS was diagnosed by the consensus criterion, which required at least 3 of the followings: WC ≥90 cm in men, ≥80 cm in women; TG ≥1.70 mmol/L; HDL <1.03 mmol/L in men, <1.29 mmol/L in women; systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥85 mmHg; and FG ≥5.6 mmol/L.

Thyroid function subgroups were determined in 2 methods. In the first method, hyperthyroidism was defined as TSH <0.3 µIU/mL, hypothyroidism as TSH >5.0 µIU/mL. Then hypothyroidism was further divided into mild hypothyroidism subgroup (5.0 µIU/mL < TSH ≤10.0 µIU/mL) and overt hypothyroidism subgroup (TSH >10.0 µIU/mL). Because upper reference of 2.5 µIU/mL was recommended by guidelines, euthyroidism was further divided into perfect function subgroup (0.3 µIU/mL < TSH ≤2.5 µIU/mL) and normal function subgroup (2.5 µIU/mL < TSH ≤5.0 µIU/mL). In the second method, TSH, FT3, and FT4 were divided based on quartiles of the measurements. Age subgroups 1 to 6 were defined according to the followings, respectively: age ≤25 years, 25 years < age ≤35 years, 35 years < age ≤45 years, 45 years < age ≤55 years, 55 years < age ≤65 years, age > 65 years.

Statistical Analysis
All data were presented as mean ± standard deviation. Differences of indices between groups or subgroups were analyzed by independent sample’s t-test. Pearson bivariate correlation was made among variables. Odds ratios (ORs) for MS with 95% confidence intervals were calculated by binary logistic regression models. Statistical Package for Social Sciences (SPSS version 17.0, Chicago, IL) was used to conduct statistics and significance was defined as P < 0.05.

RESULTS

Characteristics of the Participants in Different Genders
There were significant differences in all parameters with respect to opposite gender (Table 1). Males were younger than females, yet BMI, MC, SBP, and DBP in males was higher than in females. TSH was lower in males than in females, while FT3 and FT4 were higher in males than in females. TC and HDL were lower in males than in females, yet BMI, MC, SBP, and DBP in males was higher than in females. Besides, indices representing hepatic and renal functions were higher in males than in females.

Prevalence of MS in Different Genders
Overall prevalence of MS was 35.55% (4926/13,855) in our population. Males (41.95%, 3580/8532 cases) had significantly higher MS prevalence than females (25.29%, 1346/5323 cases), with a Chi-square value of 195.341 (P < 0.01). Age cast significant differences on the prevalence of MS, rendering a crisscross pattern (Figure 1). The prevalence of MS showed an increasing tendency in males from the youngest age to the age range of 45 to 55 years, and then stayed roughly in the plateau.
level till the highest age subgroup (Chi-square value = 101.954, \( P < 0.01 \)). In females, MS prevalence tendency increased from the youngest to the eldest, while the significantly sharp increase of MS prevalence started from the middle age to the eldest (Chi-square value = 676.323, \( P < 0.01 \)). Males, with the age of younger than 45 years, had significantly higher MS prevalence than females \( (P < 0.01) \). However, after menopause (older than 65 years), females had significantly higher MS prevalence than males \( (P < 0.01) \).

MS prevalence according to various thyroid functional status demonstrated different patterns (Figure 2). First, MS prevalence was significantly higher in males than in females in all thyroid functional status \( (P < 0.01) \), except for hyperthyroidism when TSH < 0.3 \( \mu \)IU/mL. Second, MS prevalence displayed a rising trend along with the increase of TSH levels, especially for women (for males, Chi-square value = 9.335, \( P = 0.053 \); for females, Chi-square value = 34.876, \( P < 0.01 \)).

**TABLE 1. Population Characteristics Based on Different Genders**

| Case number | Total | Male | Female | T Value |
|-------------|-------|------|--------|---------|
| Age, years  | 48.61 ± 10.75 | 48.46 ± 10.45 | 48.87 ± 11.21 | -2.171* |
| BMI, kg/m²  | 25.55 ± 3.47 | 26.29 ± 3.24 | 24.35 ± 3.49 | 33.335** |
| WC, cm      | 86.85 ± 10.74 | 91.21 ± 8.93 | 79.87 ± 9.66 | 70.460** |
| SBP, mmHg   | 125.61 ± 17.71 | 127.32 ± 16.31 | 122.86 ± 19.43 | 14.541** |
| TG, mmol/L  | 110.20 ± 11.96 | 82.84 ± 11.62 | 75.50 ± 11.07 | 36.840** |
| FT3, pmol/L | 2.51 ± 1.59 | 2.17 ± 2.92 | 3.06 ± 4.39 | -14.219** |
| FT4, pmol/L | 5.24 ± 0.86 | 5.43 ± 0.83 | 4.93 ± 0.81 | 34.929** |
| TC, mmol/L  | 16.27 ± 2.76 | 16.76 ± 2.58 | 15.48 ± 2.84 | 27.457** |
| TG, mmol/L  | 1.74 ± 1.34 | 1.98 ± 1.47 | 1.36 ± 0.99 | 27.324** |
| LDL, mmol/L | 3.09 ± 0.88 | 3.11 ± 0.86 | 3.06 ± 0.91 | 2.740** |
| HDL, mmol/L | 1.34 ± 0.36 | 1.23 ± 0.31 | 1.52 ± 0.37 | -51.515** |
| ALT, IU/L   | 23.69 ± 20.78 | 27.44 ± 23.65 | 17.64 ± 12.99 | 27.674** |
| TBIL, μmol/L| 11.98 ± 5.41 | 13.16 ± 5.70 | 10.10 ± 4.26 | 33.723** |
| BUN, mmol/L | 4.72 ± 1.34 | 4.95 ± 1.31 | 4.35 ± 1.30 | 26.165** |
| UA, μmol/L  | 329.96 ± 87.42 | 370.64 ± 76.67 | 264.76 ± 59.72 | 85.818** |
| Cr, μmol/L  | 73.45 ± 14.97 | 81.03 ± 11.98 | 61.29 ± 10.65 | 98.423** |
| FG, kg/m²   | 5.42 ± 1.21 | 5.56 ± 1.30 | 5.21 ± 1.01 | 16.879** |

**FIGURE 1.** Prevalence of MS in different age subgroups. Age subgroups 1 to 6 referred to the followings: age <25 years, 25 years < age < 35 years, 35 years < age < 45 years, 45 years ≤ age < 55 years, 55 years ≤ age < 65 years, age ≥ 65 years. MS = metabolic syndrome. *, difference of prevalence between gender was significant at 0.05; #, difference of prevalence between gender was significant at 0.01.

**FIGURE 2.** Prevalence of MS in different TSH subgroups. TSH subgroups 1 to 5 referred to the followings: TSH ≤ 0.3 μIU/mL, 0.3 μIU/mL < TSH ≤ 2.5 μIU/mL, 2.5 μIU/mL < TSH ≤ 5.0 μIU/mL, 5.0 μIU/mL < TSH ≤ 10.0 μIU/mL, TSH > 10.0 μIU/mL. MS = metabolic syndrome. #, difference of prevalence between gender was significant at 0.05; *, difference of prevalence between gender was significant at 0.01.
TABLE 2. Incidence of Hypothyroidism and Hyperthyroidism on Different Genders

| Incidence (and Case Number Count) in Different Age Subgroups, years | Male | Female |
|---------------------------------------------------------------|------|--------|
| Age ≤ 25                                                      | 96.15% (50) | 88.24% (45) |
| 25 < Age ≤ 35                                                 | 97.55% (718) | 93.82% (486) |
| 35 < Age ≤ 45                                                 | 97.37% (2744) | 91.12% (1499) |
| 45 < Age ≤ 55                                                 | 97.00% (2744) | 87.56% (1450) |
| 55 < Age ≤ 65                                                 | 95.24% (1522) | 82.96% (842) |
| Age > 65                                                     | 90.18% (450) | 82.88% (363) |
| **Total**                                                     | 96.44% (8228) | 88.01% (4685) |

| Hypothyroidism | 3.85% (2) | 9.80% (5) |
| Hyperthyroidism | 0.00% (0) | 1.96% (1) |

| Hypothyroidism | 1.510 | 1.098 |
| Hyperthyroidism | 0.39% (2) | 0.13% (1) |
| **Total** | 2.539 | 1.370 |

* P < 0.05.
** P < 0.01.
† Hypothyroidism defined as TSH > 5.0 μIU/mL, hyperthyroidism defined as TSH < 0.3 μIU/mL.
‡ Comparing the incidence of hypothyroidism and/or hyperthyroidism between males and females by Chi-square method.

Incidence of Thyroid Dysfunction in Different Genders

Our population demonstrated an incidence of thyroid dysfunction of 6.80% (942/13,855), with hypothyroidism of 5.90% (818/13,855) and hyperthyroidism of 0.89% (124/13,855), the former significantly higher than the latter (Chi-square value = 494.771, P < 0.01). Females had significantly higher incidence of hypothyroidism and hypothyroidism than males (Table 2). When we analyzed the detailed incidences divided by age, most age subgroups demonstrated the same pattern of differences between the opposite gender, except for the people of the youngest age. However, the fact that there were only a very small number of participants in the age subgroup of ≤25 years, the incidences calculated here might not be representative. Another important finding was that there existed a significant tendency of increasing hypothyroidism incidence with aging (except for the people of the youngest age) for both gender. Chi-square test showed significances in males (Chi-square value = 85.487, P < 0.01) and in females (Chi-square value = 60.820, P < 0.01).

Correlations of Key Variables in Different Genders

Age was indicated to have correlations with nearly all of the variables, and correlation coefficients were significantly higher (Table 3). Age and BMI showed positive correlation in females yet negative correlation in males. In both genders, age and TSH showed positive correlation, while age and FT3 showed negative correlation. Age showed positive correlation with WC, SBP, DBP, TC, LDL, BUN, Cr, and FG in both genders, yet negative correlation with TG in males and negative correlation with HDL in females.

TSH demonstrated significant negative relationships with FT3 and FT4 for both genders. In males, positive relationships were demonstrated for age, SBP, TC, LDL, and Cr. In females, positive relationships were demonstrated for age, BMI, WC, SBP, DBP, TC, TG, LDL, ALT, BUN, UA, and Cr.

Risks of Developing MS in Different Genders

Five binary logistic regression models were utilized to calculate the risks of developing MS (Table 4). The 1st model designated thyroid functional states as the categorical variables, and the subgroup of TSH < 0.3 μIU/mL was determined as reference. Age, FT3, and FT4 were included as covariates. This model did not reveal any significant risks of MS in either sex. The 2nd model designated TSH quartiles as the categorical variables, and the lowest quartile was determined as reference. Significantly increased risk was demonstrated in quartile 4 for males, while in quartiles 3 and 4 for females. The 3rd model designated FT3 quartiles as the categorical variables, and the lowest quartile was determined as reference. Age, TSH, and FT4 were included as covariates. Significantly increased risk was demonstrated in quartile 2 to 4 for females, yet no risk was displayed in males. The 4th model designated FT4 quartiles as the categorical variables, and the lowest quartile was determined as reference. Age, TSH, and FT3 were included as covariates. This model did not indicate any significant risks of MS in either sex. The 5th model designated age subgroups as the categorical variables, and the subgroup of age ≤25 years was determined as reference. TSH, FT3, and FT4 were included as covariates. Significantly increased risks were shown in both genders, with ORs in females (4.408–58.455) higher than ORs in males (2.588–4.943).

DISCUSSION

During recent decades, nutritional, demographic, epidemiological, and socioeconomic transitions have been occurring in China. Lifestyle of large proportions of the Chinese population has been drastically changed to an excessive energy-dense diet intaking and sedentary occupational environment pattern. In parallel with the lifestyle changes, dysmetabolic phenotypes, such as hyperglycemia, obesity, and hypertension, are rising to epidemic levels. WHO estimates that, globally, there are more than 1 billion adults overweight and 300 million obese people. MS defines a constellation of such metabolic...
risk factors, it is estimated at least 1 in 3 adults in USA meet the MS criteria. In developing countries, the prevalence of MS also increases. Misra and Khurana compiled the data and reported MS prevalence in developing countries in 2008, for example, sub-Saharan Africa and Middle East countries (33.5%), India (28.8%), Turkey (33.4%), Iran (33.7%), Venezuela (31.2%), and Brazil (25.4%). MS is associated with an increased risk of diabetes, and a number of cardiovascular events, such as myocardial infarction, stroke, and heart failure. The cost of metabolic abnormality is also astronomical. In mainland China, the total medical costs attributable to overweight and obesity alone were estimated at 21.1 billion Yuans in 2003, accounting for 3.7% of national total medical costs.28

Yet, after menopause, with the decline of circulating estrogens, the reduced risk of cardiovascular disease in women compared to men before menopause has been speculated to be related to a reduced abdominal fat accumulation in women.21

Menopause is associated with an increase in all single components of the MS (ie, with the development of android obesity, increased risk of diabetes, and a number of cardiovascular diseases).22,23 Various forms of thyroid dysfunction and Hashimoto thyroiditis are more common in women, and the overall incidence increases with age in both sexes (TSH distributional shift with age), especially in women.35–37

Metabolism has a sex dimorphism, which results in different cardiovascular disease risks for men and women. In particular, the reduced risk of cardiovascular disease in women compared to men before menopause has been speculated to be related to a reduced abdominal fat accumulation in women.31

Yet, after menopause, with the decline of circulating estrogens, the concentrations of lipoproteins, as well as body fat distribution in females will shift toward a central or android pattern more similar to males.32

**TABLE 3. Pearson Bivariate Correlations Among Key Variables Based on Different Genders**

| TSH  | FT3    | FT4    | Age  | TSH  | FT3    | FT4    | Age  |
|------|--------|--------|------|------|--------|--------|------|
| Age  | 0.044**| −0.177**| −0.131**| −     | 0.058**| −0.029*| 0.006|−     |
| BMI  | 0.012  | 0.017  | −0.055**| −0.027*| 0.040**| 0.022  | −0.026| 0.290**|
| WC   | 0.017  | 0.005  | −0.059**| 0.115**| 0.054**| 0.028* | −0.014| 0.435**|
| SBP  | 0.022* | −0.040**| −0.017 | 0.285**| 0.049**| 0.034* | 0.042*| 0.561**|
| DBP  | 0.020  | −0.004 | 0.015  | 0.115**| 0.031* | 0.036**| 0.046**| 0.326**|
| TSH  | −0.103**| −0.145**| −0.145**| 0.044**| −0.149**| 0.527**| −0.117| 0.643**|
| FT3  | −0.103**| 0.527**| −0.131**| −     | −0.149**| 0.643**| −0.029| −     |
| FT4  | −0.145**| 0.527**| −0.131**| −     | −0.131**| 0.643**| −0.006| −     |
| TG   | 0.027* | −0.080**| 0.014  | 0.053**| 0.074**| −0.097**| −0.005| 0.370**|
| TG   | 0.002  | −0.042**| 0.003  | −0.074| 0.074**| −0.014 | 0.002 | 0.230**|
| HDL  | −0.011 | −0.038**| −0.004 | 0.066**| 0.061**| −0.081**| −0.007| 0.337**|
| ALT  | 0.008  | 0.045**| −0.004 | −0.151**| 0.032* | 0.064**| 0.023 | 0.149**|
| TBIL | −0.003 | 0.001  | 0.073**| −0.003| −0.034*| 0.018  | 0.070**| 0.016|
| BUN  | 0.015  | −0.036**| −0.014 | 0.177**| 0.047**| −0.026 | −0.005| 0.295**|
| UA   | 0.002  | 0.013  | −0.025* | −0.121**| 0.037**| 0.015  | 0.040**| 0.203**|
| Cr   | 0.066**| −0.090**| −0.026 | 0.057**| 0.080**| −0.148**| −0.054**| 0.158**|
| FG   | 0.011  | −0.043**| 0.022  | 0.147**| −0.003 | 0.021  | 0.063**| 0.290**|

ALT = alanine aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, FG = fasting glucose, FT3 = free triiodothyronine, FT4 = free thyroxine, HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, SBP = systolic blood pressure, TBIL = total bilirubin, TC = total cholesterol, TG = triglycerides, TSH = thyroid stimulation hormone, UA = uric acid, WC = waist circumference.

* P < 0.05.
** P < 0.01.
Thyroid hormones play important roles in metabolism, and cardiovascular system is also very sensitive to thyroid function. The mechanistic explanations for the relationship between thyroid hormones and MS have not been fully elucidated, although the effects are believed to be mediated at both genomic and nongenomic levels. There are several possible postulations put forward as the followings. Thyroid hormones can play a role in the development of insulin resistance, which is intrinsically associated with thyroid, which eventually leads to MS as a final result. For instance, hypothyroidism can increase body weight, and TSH is identified to be positively related with BMI and obesity, even within the normal range. Increasing TSH in overt and mild hypothyroidism is also found to be associated with unfavorable lipid concentrations (like hypercholesterolemia and decreased HDL levels), as well as blood pressure. Thyroid function also has an effect on the activity of cholesteryl ester transfer protein and hepatic lipase, which alters HDL metabolism. As a result, T3 is negatively associated with HDL.

Aging is defined as a series of morphological and functional changes taking place overtime, which denotes deterioration of the biological functions after an organism has attained its maximal reproductive potential. The most important gender differences in aging are related to the reproductive organs. Women experience a rapid decline in sex hormones during the cessation of menses, while men experience a slow and continuous decline. Age is also an important factor influencing the association between MS and thyroid function. In fact, aging of the population was regarded by Lao et al. as one of the major factors driving dramatic MS escalation. Bensenor et al. demonstrated that aging promotes a natural decrease in the pituitary TSH secretion and deiodination of T4, while increases the occurrence of antithyroglobulin and antithyryoperoxidase antibodies. During aging, reproductive and nonreproductive actions of sex steroid hormones decrease significantly. Gender differences in prevalence, time of onset and severity of MS, and its cardiovascular consequences are results of the different rate of decrease of sexual hormones in males and females. We showed that aging resulted in increased prevalence MS and thyroid dysfunction (Figure 1 and Table 2). Our investigation

**TABLE 4. The Risks of Developing MS in Different Genders**

| Parameter Values | OR (CI) |
|------------------|---------|
| **Males**        |         |
| TSH functions†   | (μIU/mL) |
| Hyperthyroidism  | TSH ≤ 0.3 (reference) – |
| Perfect function | 0.3 < TSH ≤ 2.5 1.440 (0.735–2.821) |
| Normal function  | 2.5 < TSH ≤ 5.0 1.574 (0.798–3.101) |
| Mild hypothyroidism | 5.0 < TSH ≤ 10.0 1.297 (0.625–2.690) |
| Overt hypothyroidism | TSH > 10 2.151 (0.857–5.396) |
| TSH quartiles‡   | (μIU/mL) |
| Quartile 1       | TSH ≤ 1.324 (reference) – |
| Quartile 2       | 1.324 < TSH ≤ 1.815 1.106 (0.978–1.250) |
| Quartile 3       | 1.815 < TSH ≤ 2.518 1.119 (0.989–1.265) |
| Quartile 4       | TSH > 2.518 1.164 (1.029–1.317) |
| FT4 quartiles§   | (pmol/L) |
| Quartile 1       | FT3 ≤ 5.070 (reference) – |
| Quartile 2       | 5.070 < FT3 ≤ 5.390 0.995 (0.880–1.125) |
| Quartile 3       | 5.390 < FT3 ≤ 5.710 0.975 (0.860–1.106) |
| Quartile 4       | FT3 > 5.710 1.084 (0.951–1.236) |
| FT4 quartiles§   | (pmol/L) |
| Quartile 1       | FT4 ≤ 15.260 (reference) – |
| Quartile 2       | 15.260 < FT4 ≤ 16.610 1.083 (0.955–1.229) |
| Quartile 3       | 16.610 < FT4 ≤ 18.100 1.112 (0.982–1.258) |
| Quartile 4       | FT4 > 18.100 1.016 (0.898–1.150) |
| Age subgroups‖   | (years) |
| Age subgroup 1   | Age ≤ 25 (reference) – |
| Age subgroup 2   | 25 < Age ≤ 35 2.588 (1.149–5.833) † |
| Age subgroup 3   | 35 < Age ≤ 45 4.243 (1.906–9.445) ‡ |
| Age subgroup 4   | 45 < Age ≤ 55 5.455 (2.450–12.145) ‡ |
| Age subgroup 5   | 55 < Age ≤ 65 5.165 (2.313–11.533) ‡ |
| Age subgroup 6   | Age > 65 4.943 (2.183–11.192) ‡ |

| Parameter Values | OR (CI) |
|------------------|---------|
| **Females**      |         |
| TSH functions†   | (μIU/mL) |
| Hyperthyroidism  | TSH ≤ 0.3 (reference) – |
| Perfect function | 0.3 < TSH ≤ 2.5 1.318 (0.711–2.443) |
| Normal function  | 2.5 < TSH ≤ 5.0 1.801 (0.968–3.350) |
| Mild hypothyroidism | 5.0 < TSH ≤ 10.0 1.535 (0.801–2.942) |
| Overt hypothyroidism | TSH > 10 1.969 (0.888–4.364) |

CI = confidence interval, FT3 = free triiodothyronine, FT4 = free thyroxine, OR = odds ratio, TSH = thyroid stimulation hormone.

† Logistic regression model included age, FT3 and FT4 as covariates.
‡ Logistic regression model included age, TSH and FT4 as covariates.
§ Logistic regression model included age, TSH and FT3 as covariates.
‖ Logistic regression model included TSH, FT3 and FT4 as covariates.
was in line with the previous reports.\textsuperscript{5,56} We also demonstrated that the increase rate of MS in women from before menopause to after menopause was very dramatic, rendering a crisscross pattern (Figure 1), which was in confirmative with our previous study\textsuperscript{22} and others.\textsuperscript{8} Binary logistic regression models revealed that aging was much more effective than thyroid function parameters (TSH or FT3) to engender an enhanced risk of MS (Table 4).

One of our findings was that higher FT3 was a risk factor for MS, which appeared contradictory to another of our findings that higher TSH was a risk factor for MS. In fact, this paradoxical phenomenon has been noticed by several previous investigations.\textsuperscript{46,48,49} Positive associations between FT3 and metabolic status (eg, BMI) were reported, this is in contrast to FT4, which had negative relation with metabolic traits. And higher FT3 level was reported to be associated with various markers of unfavorable metabolic profile and cardiovascular risk.\textsuperscript{46,48,49} Roef et al\textsuperscript{46} showed that in healthy euthyroid middle-aged men and women, higher FT3 levels, lower FT4 levels, and thus a higher FT3-to-FT4 ratio were consistently associated with various markers of unfavorable metabolic profile and cardiovascular risk. Ortega et al\textsuperscript{49} demonstrated that FT3, not FT4, concentrations were associated with direct and indirect measurements of insulin secretion, independent of insulin sensitivity, and glucose concentrations in euthyroid individuals. This study indicated that T3 concentrations might play a role in the regulation of insulin secretion. The main mechanism of this phenomenon has been considered as that changes in deiodinase 1 and/or 2 catalytic properties in subjects with higher fat mass and unfavorable metabolic profile lead to higher conversion of T4 to T3.\textsuperscript{50} Indeed, Ortega et al\textsuperscript{50} demonstrated that activity of deiodinases 1 was increased in omental and subcutaneous fat of obese subjects when compared with nonobese subjects and correlated well with BMI. Increased levels of deiodinases 1 in adipose tissue of obese subjects might reflect the stimulation of this enzyme by locally formed leptin. And, in turn, enhanced production of T3 by deiodinases 1 in fat could be involved in the modulation of adipose tissue metabolism by leptin. As for other possible mechanisms, Roef et al\textsuperscript{46} postulated that an adverse metabolic profile could theoretically lead to an altered thyroid hormone secretion by the thyroid gland itself, with a relatively higher T3-secretion. Besides, since both higher TSH levels as well as a higher FT3-to-FT4 ratio could indicate a lower iodine pool, and since TSH was also positively related to the FT3-to-FT4 ratio, another mechanism underlying the higher FT3-to-FT4 ratio (and the higher TSH levels) in subjects with a less favorable metabolic profile could be a lower iodine intake in the diet or a decreased absorption.

The net effect of gender and age on the association between thyroid dysfunction and MS is the most important objective of our analysis. We found that women have more increased risks of developing MS than men, under the circumstances of high TSH, high FT3, and advanced age (Table 4). We consider the reason of these results could be that estrogen’s protective effects on MS are overshadowed and overwhelmed by the female inclination of thyroid dysfunction. When women age, postmenopausal phenomenon will have compromised estrogen milieu, yet enhanced thyroid abnormality. Under such circumstances, increased changes of TSH and FT3 can herald MS risks. MS and thyroid dysfunction are 2 common endocrine disorders with a substantial overlap, and both are associated with significant morbidity and mortality. Both diseases are becoming major public health problems in China, which underscore the urgent need to develop comprehensive strategies aimed at the prevention and treatment of the diseases to reduce increased socioeconomic, medical and societal burdens, and ramifications in China. Urgent public health actions are needed to control this challenge in China. Limitations of our study deserve additional comments. First, this was a cross-sectional study, so a cause and effect relationship cannot be discerned. Further prospective studies should be carried out to answer the causality question. Second, we did not obtain data of thyroid antibodies, which might influence thyroid hormone. So, we could not comment on the putative impact of thyroid autoimmunity. Third, we did not measure sex hormones in our population because of the budget shortage. Finally, we checked TSH only once, we did not double check TSH measurement in the study.

In conclusion, we found that serum TSH and FT3 levels were positively associated with MS. And females had higher risks than males. Moreover, aging is an important risk factor for MS. Our results suggest the necessity of monitoring TSH and FT3 in the population for MS risk assessment, especially elder women.

ACKNOWLEDGMENTS

The authors thank National Key Clinical Specialty Project (awarded to the Departments of Nuclear Medicine and Radiology). The authors also thank Tianjin Medical University General Hospital New Century Excellent Talent Program; Young and Middle-aged Innovative Talent Training Program from Tianjin Education Committee; and Talent Fostering Program (the 131 Project) from Tianjin Education Committee, Tianjin Human Resources and Social Security Bureau (awarded to Zhaowei Meng) for the support.

REFERENCES

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 1998;15:539–553.
2. Expert Panel on Detection E. Treatment of high blood cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752.
4. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
5. Lao XQ, Ma WJ, Sobko T, et al. Dramatic escalation in metabolic syndrome and cardiovascular risk in a Chinese population experiencing rapid economic development. BMC Pub Health. 2014;14:983.
6. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365:1398–1405.
7. Xu S, Gao B, Xing Y, et al. Gender differences in the prevalence and development of metabolic syndrome in Chinese population with abdominal obesity. *PloS One*. 2013;8:e78270.

8. Song QB, Zhao Y, Liu YQ, et al. Sex difference in the prevalence of metabolic syndrome and cardiovascular-related risk factors in urban adults from 33 communities of China: The CHPSNE study. *Diabetes Vasc Dis Res*. 2015;12:189–198.

9. Yousefzadeh G, Sheikhhvatan M. Age and gender differences in the clustering of metabolic syndrome combinations: a prospective cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS). *Diabetes Metab Syndr*. 2013.

10. Guarner-Lans V, Rubio-Ruiz ME, Perez-Llanes I, et al. Relation of aging and sex hormones to metabolic syndrome and cardiovascular disease. *Exp Gerontol.* 2011;46:517–523.

11. Walsh JP, Brenner AP, Bullsara MK, et al. Thyroid dysfunction and serum lipids: a community-based study. *Clin Endocrinol*. 2005;63:670–679.

12. Wang F, Tan Y, Wang C, et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. *J Clin Endocrinol Metab*. 2012;97:2724–2731.

13. Xu C, Yang X, Liu W, et al. Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a cross-sectional design. *Nutr Metab*. 2012;9:44.

14. Erdogan M, Canataroglu A, Ganadagli S, et al. Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters. *J Endocrinol Invest*. 2011;34:488–492.

15. Waring AC, Rodondi N, Harrison S, et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. *Clin Endocrinol*. 2012;76:911–918.

16. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. *Clin Endocrinol*. 2010;72:696–701.

17. Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. *Korean J Inter Med*. 2013;28:180–186.

18. Garduno-Garcia Jde J, Alvirde-Garcia U, Lopez-Carrasco G, et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. *Eur J Endocrinol*. 2010;163:273–278.

19. Bakiner O, Bozkirli E, Cavlak G, et al. Are plasma thyroid-stimulating hormone levels associated with degree of obesity and metabolic syndrome in euthyroid obese patients? A Turkish cohort study. *IsRN Rheumatol*. 2014;2014:803028.

20. Liu L, Lou S, Xu K, et al. Relationship between lifestyle choices and hyperuricemia in Chinese men and women. *Clin Rheumatol*. 2013;32:233–239.

21. Zhang J, Meng Z, Zhang Q, et al. Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese. *Clin Rheumatol*. 2015.

22. Zhang Q, Lou S, Meng Z, et al. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. *Clin Rheumatol*. 2011;30:777–787.

23. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid*. 2012;22:1200–1235.

24. Kratzsch J, Fiedler GM, Leichtle A, et al. New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. *Clin Chem*. 2005;51:1480–1486.

25. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. *J Clin Endocrinol Metab*. 2008;93:S9–S30.

26. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonized definition among adults in the US. *J Diabetes*. 2010;2:180–193.

27. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. *Clin Res Cardiol*. 2006;95:136–147.

28. Zhao W, Zhai Y, Hu J, et al. Economic burden of obesity-related chronic diseases in Mainland China. *Obes Rev*. 2008;9(Suppl 1):62–67.

29. Huang C, Yu H, Koplan JP. Can China diminish its burden of non-communicable diseases and injuries by promoting health in its policies, practices, and incentives? *Lancet*. 2014;384:783–792.

30. Zhang J, Shi XM, Liang XF. [Economic costs of both overweight and obesity among Chinese urban and rural residents, in 2010]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2013;34:598–600.

31. Van Pelt RE, Jankowski CM, Gozansky WS, et al. Sex differences in the association of thigh fat and metabolic risk in older adults. *Obesity*. 2011;19:422–428.

32. Pellegrini M, Paliotti V, Marin R, et al. Role of the sex hormone estrogen in the prevention of lipid disorder. *Curr Med Chem*. 2014;21:2734–2742.

33. Regitz-Zagrosek V, Lehmkuhl E, Mahmoudzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. *Gender Med*. 2007;4(Suppl B):S162–S177.

34. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes Care*. 2005;28:1769–1778.

35. Tognini S, Polini A, Pasqualetti G, et al. Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. *Thyroid*. 2012;22:1096–1103.

36. Cooper DS, Biondi B. Subclinical thyroid disease. *Lancet*. 2012;379:1142–1154.

37. Jones DD, May KE, Geraci SA. Subclinical thyroid disease. *Am J Med*. 2010;123:502–504.

38. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA*. 2010;304:1365–1374.

39. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. *Thyroid*. 2002;12:459–466.

40. Maratou E, Hadjidakis DJ, Peppa M, et al. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. *Eur J Endocrinol*. 2010;163:625–630.

41. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol*. 2009;160:785–790.

42. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. *Endocr Rev*. 2008;29:777–822.

43. de Moura Souza A, Sichieri R. Association between serum TSH concentration within the normal range and adiposity. *Eur J Endocrinol*. 2011;165:11–15.

44. Liu D, Jiang F, Shan Z, et al. A cross-sectional survey of relationship between serum TSH level and blood pressure. *J Hum Hypertens*. 2010;24:134–138.

45. Tan KC, Shiu SW, Kung AW. Effect of thyroid dysfunction on high-density lipoprotein subclass metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. *J Clin Endocrinol Metab*. 1998;83:2921–2924.
46. Roef GL, Rietzschel ER, Van Daele CM, et al. Triiodothyronine and free thyroxine levels are differentially associated with metabolic profile and adiposity-related cardiovascular risk markers in euthyroid middle-aged subjects. *Thyroid*. 2014;24:223–231.

47. Bensenor IM, Olmos RD, Lotufo PA. Hypothyroidism in the elderly: diagnosis and management. *Clin Intervent Aging*. 2012;7:97–111.

48. De Pergola G, Ciampolillo A, Paolotti S, et al. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. *Clin Endocrinol*. 2007;67:265–269.

49. Ortega E, Koska J, Pannacciulli N, et al. Free triiodothyronine plasma concentrations are positively associated with insulin secretion in euthyroid individuals. *Eur J Endocrinol*. 2008;158:217–221.

50. Ortega FJ, Jilkova ZM, Moreno-Navarrete JM, et al. Type I iodothyronine 5'-deiodinase mRNA and activity is increased in adipose tissue of obese subjects. *Int J Obes*. 2012;36:320–324.